Rapport Therapeutics (RAPP) Cash from Investing Activities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Cash from Investing Activities data on file, last reported at $37.9 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 80.41% year-over-year to $37.9 million in Q1 2026; TTM through Mar 2026 was -$170.6 million, a 59.13% decrease from a year earlier, with the FY2025 full-year figure at -$187.5 million, down 10.19% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $37.9 million, up from -$174.3 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for RAPP reached as high as $37.9 million in Q1 2026 and fell as low as -$174.3 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$36.2 million across 4 years, with a median of -$41.9 million in 2024.
• Across the five-year window, Cash from Investing Activities tumbled 101901.92% in 2024 and soared 150.16% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$78.7 million in 2023, then soared by 140.59% to $31.9 million in 2024, then slumped by 645.96% to -$174.3 million in 2025, then surged by 121.76% to $37.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $37.9 million in Q1 2026, -$174.3 million in Q4 2025, and -$56.8 million in Q3 2025.